Alector ALEC
Alector FY 2022: revenue $133.6M; diluted EPS −$1.62
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0000950170-23-005111
- Document
- 10-K
Key figures from this report
These are the numbers Alector reported for the year ended Dec 31, 2022, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$133.6MNo year-earlier figure tagged10-K income statement, on EDGAR
- Net income−$133.3MAgainst −$36.3M in FY 202110-K income statement, on EDGAR
- Diluted EPS−$1.62Against −$0.45 in FY 202110-K income statement, on EDGAR
- Cash and cash equivalents$154.3M−53% from $329.2M in FY 2021Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations−$20.3M−107% from $298.6M in FY 202110-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.
- Protalix BioTherapeutics PLX public float $113M, Jun 30, 2025
- Fate Therapeutics FATE public float $113M, Jun 30, 2025
- Caribou Biosciences CRBU public float $113M, Jun 30, 2025
- Protara Therapeutics PRTO public float $112M, Jun 30, 2025
- TuHURA Biosciences HURA public float $111M, Jun 30, 2025
